Changeflow GovPing Healthcare & Life Sciences Plant Glycoside Microcapsule for Oral Care, Nat...
Routine Rule Added Final

Plant Glycoside Microcapsule for Oral Care, Natural Wax Coating

Email

Summary

The USPTO has published application US20260108433A1 disclosing a plant glycoside microcapsule with a core-shell structure for oral care use, wherein the shell is composed of natural wax (beeswax and carnauba) at a core-to-shell mass ratio of 1:(0.3–0.7). The application, filed on September 18, 2025, names five inventors and specifies the wax mixture ratio as 1:(0–0.2) for beeswax to carnauba. This is a patent publication event; no compliance obligations arise. Companies developing oral care products containing encapsulated plant glycosides should monitor the prosecution of this application to assess potential future exclusivity.

“The present application belongs to the field of oral care materials. Specifically disclosed are a plant glycoside microcapsule, and a preparation method and application thereof.”

USPTO , verbatim from source
Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.

What changed

The USPTO published application US20260108433A1 disclosing a plant glycoside microcapsule with a core-shell structure for oral care, where the shell comprises natural wax (beeswax and carnauba) at a core-to-shell mass ratio of 1:(0.3–0.7) and a beeswax-to-carnauba ratio of 1:(0–0.2). The invention uses plant glycoside extract as the encapsulated core material.

Affected parties in the oral care product, pharmaceutical, and consumer goods sectors should monitor the prosecution of this application for potential competitive implications. If the patent grants, it could restrict third-party use of encapsulated plant glycoside compositions in oral care formulations using the specified natural wax coating system.

Archived snapshot

Apr 24, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

Plant Glycoside Microcapsule, and Preparation Method and Application

Application US20260108433A1 Kind: A1 Apr 23, 2026

Inventors

Lei XIAO, Jinlian HUANG, Xiaoxi LI, Tengfei QU, Lulu DONG

Abstract

The present application belongs to the field of oral care materials. Specifically disclosed are a plant glycoside microcapsule, and a preparation method and application thereof. The microcapsule has a core-shell structure, and a shell of the microcapsule is a natural wax; a mass ratio of a core of the microcapsule to the shell of the microcapsule is 1:(0.3-0.7); and the natural wax includes a mixture of beeswax and carnauba in a mass ratio of 1:(0-0.2). The present application uses the natural wax as a coating material, and a plant glycoside extract is encapsulated into the microcapsule. The microcapsule is smooth in surface and compact in encapsulation.

CPC Classifications

A61K 8/11 A61K 8/602 A61K 8/731 A61K 8/732 A61K 8/922 A61K 8/925 A61Q 11/00

Filing Date

2025-09-18

Application No.

19333193

View original document →

Get daily alerts for USPTO Patent Applications - Pharma (A61K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Instrument
Rule
Branch
Executive
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US20260108433A1

Who this affects

Applies to
Manufacturers Healthcare providers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent application IP filing
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Consumer Protection

Get alerts for this source

We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!